HC Wainwright Predicts Stronger Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Equities researchers at HC Wainwright increased their Q1 2025 EPS estimates for Legend Biotech in a report issued on Wednesday, March 12th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.18) per share for the quarter, up from their prior estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.07) EPS.

Legend Biotech (NASDAQ:LEGN) last released its quarterly earnings data on Tuesday, March 11th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.46. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm had revenue of $186.50 million for the quarter, compared to analysts’ expectations of $179.00 million. During the same quarter in the previous year, the company earned ($0.40) earnings per share. The company’s revenue for the quarter was up 134.6% compared to the same quarter last year.

Several other equities analysts have also recently issued reports on LEGN. Morgan Stanley reduced their price target on shares of Legend Biotech from $82.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday. Guggenheim reiterated a “neutral” rating on shares of Legend Biotech in a research report on Wednesday, March 12th. Piper Sandler reiterated an “overweight” rating and set a $78.00 price target on shares of Legend Biotech in a research report on Monday, December 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $83.00 price target on shares of Legend Biotech in a research report on Monday, December 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $86.00 price objective on shares of Legend Biotech in a research note on Monday, December 9th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Legend Biotech has an average rating of “Moderate Buy” and a consensus price target of $79.17.

Legend Biotech Price Performance

Shares of NASDAQ LEGN opened at $37.94 on Monday. Legend Biotech has a 1 year low of $30.17 and a 1 year high of $65.45. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90. The company’s 50-day moving average is $35.75 and its 200 day moving average is $40.61. The stock has a market capitalization of $6.93 billion, a P/E ratio of -39.94 and a beta of 0.19.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Exane Asset Management bought a new position in shares of Legend Biotech in the fourth quarter worth approximately $2,284,000. Matthews International Capital Management LLC raised its holdings in shares of Legend Biotech by 14.9% during the fourth quarter. Matthews International Capital Management LLC now owns 1,185,516 shares of the company’s stock valued at $38,577,000 after purchasing an additional 153,665 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Legend Biotech by 14.2% during the fourth quarter. Nordea Investment Management AB now owns 266,232 shares of the company’s stock valued at $8,684,000 after purchasing an additional 33,024 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of Legend Biotech during the third quarter valued at approximately $12,837,000. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Legend Biotech by 5.6% during the third quarter. Westfield Capital Management Co. LP now owns 5,038,505 shares of the company’s stock valued at $245,526,000 after purchasing an additional 266,296 shares during the last quarter. Institutional investors own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).